Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
Globe Newswire2-01-2024, 20:00
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates 31-03-2023, 15:00